Resverlogix to press on with trial of cardiovascular drug after safety review

A nice little write up about the recent DSMB review. I was thinking more about the statement in the news release: "The DSMB reviewed available study data and noted that no safety or efficacy concerns were identified," and must point out that the previous transient elevations in the liver enzyme alanine aminotransferase (ALT) was not even mentioned. That is a great sign.

BearDownAZ